Deepshitha Kiyawat
Monday, August 10, 2026
21.6
C
Bengaluru
Hot topics
The Ethics Curve
K. Hariram reports on the OPPI 50th Annual General Meeting held in Mumbai on October 21. The report also features photos from the conference. Other topics covered include the role of emotions in pharma marketing, the importance in preparing much before-hand for the next level of your pharma career and the concept of the "tipping point" and its relevance for pharma marketing.
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Sales Force Strategy in the Digital World
Does Your Company Have a Well Thought-out Strategy on...
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams
A great manager is not just a leader; they...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Hot topics
Will Omicron Wave be a Repeat Rx for Indian Pharma?
How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
Indian Pharma Market October 2021 – IQVIA Report
IPM was valued at Rs. 178,219 Cr for MAT Oct’21. The retail sector was valued at Rs. 151,183 Cr for this period contributing 85% to IPM.
IPM Growth for the month of Oct’21 as compared to the month of Oct’20 was 9.7%. This is the lowest monthly growth in the last 8 months after a low growth of 2.6% reported for Feb’21.
Corresponding to low monthly growth, IPM MAT growth also declined slightly after showing a growing trend consistently for the last 7 months from MAT Feb’21. It reported 17.3% for MAT Oct’21 as compared to 17.8% reported for MAT Sept’21.
At 15657.3 Cr, the monthly sale reported for Oct’21 is the 5th highest sale value in the last 12 months.
Opportunities for Indian Pharma
Articles by Bhaskar Chakravorty, Hanno Wolfram, K. Hariram, Krishna Singh, Shreenivas S, Chandan Kumar and Salil Kallianpur
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
Newsletter
Get important news delivered directly to your inbox and stay connected!